nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CYP3A4—Estropipate—osteoporosis	0.0393	0.158	CbGbCtD
Galantamine—CYP3A4—Calcitriol—osteoporosis	0.0393	0.158	CbGbCtD
Galantamine—CYP2D6—Cholecalciferol—osteoporosis	0.0318	0.128	CbGbCtD
Galantamine—CYP3A4—Ergocalciferol—osteoporosis	0.0314	0.126	CbGbCtD
Galantamine—CYP3A4—Raloxifene—osteoporosis	0.0262	0.105	CbGbCtD
Galantamine—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0253	0.102	CbGbCtD
Galantamine—CYP3A4—Cholecalciferol—osteoporosis	0.0202	0.0814	CbGbCtD
Galantamine—CYP3A4—Conjugated Estrogens—osteoporosis	0.0186	0.0748	CbGbCtD
Galantamine—CYP3A4—Estradiol—osteoporosis	0.0163	0.0656	CbGbCtD
Galantamine—CHRNA5—Fulvestrant—Estradiol—osteoporosis	0.012	1	CbGdCrCtD
Galantamine—Vomiting—Etidronic acid—osteoporosis	0.000577	0.000796	CcSEcCtD
Galantamine—Cough—Zoledronate—osteoporosis	0.000576	0.000795	CcSEcCtD
Galantamine—Oedema peripheral—Estradiol—osteoporosis	0.000575	0.000794	CcSEcCtD
Galantamine—Tachycardia—Pamidronate—osteoporosis	0.000575	0.000794	CcSEcCtD
Galantamine—Connective tissue disorder—Estradiol—osteoporosis	0.000574	0.000792	CcSEcCtD
Galantamine—Urethral disorder—Estradiol—osteoporosis	0.000572	0.00079	CcSEcCtD
Galantamine—Rash—Etidronic acid—osteoporosis	0.000572	0.000789	CcSEcCtD
Galantamine—Convulsion—Zoledronate—osteoporosis	0.000572	0.000789	CcSEcCtD
Galantamine—Dermatitis—Etidronic acid—osteoporosis	0.000571	0.000788	CcSEcCtD
Galantamine—Vertigo—Conjugated Estrogens—osteoporosis	0.000571	0.000788	CcSEcCtD
Galantamine—Hyperhidrosis—Pamidronate—osteoporosis	0.00057	0.000786	CcSEcCtD
Galantamine—Syncope—Conjugated Estrogens—osteoporosis	0.00057	0.000786	CcSEcCtD
Galantamine—Hypertension—Zoledronate—osteoporosis	0.00057	0.000786	CcSEcCtD
Galantamine—Hypersensitivity—Alendronate—osteoporosis	0.000569	0.000786	CcSEcCtD
Galantamine—Headache—Etidronic acid—osteoporosis	0.000568	0.000784	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000565	0.00078	CcSEcCtD
Galantamine—Asthenia—Estropipate—osteoporosis	0.000563	0.000777	CcSEcCtD
Galantamine—Visual impairment—Estradiol—osteoporosis	0.000563	0.000777	CcSEcCtD
Galantamine—Anorexia—Pamidronate—osteoporosis	0.000562	0.000775	CcSEcCtD
Galantamine—Myalgia—Zoledronate—osteoporosis	0.000562	0.000775	CcSEcCtD
Galantamine—Chest pain—Zoledronate—osteoporosis	0.000562	0.000775	CcSEcCtD
Galantamine—Arthralgia—Zoledronate—osteoporosis	0.000562	0.000775	CcSEcCtD
Galantamine—Palpitations—Conjugated Estrogens—osteoporosis	0.000561	0.000775	CcSEcCtD
Galantamine—Insomnia—Risedronate—osteoporosis	0.000561	0.000774	CcSEcCtD
Galantamine—Anxiety—Zoledronate—osteoporosis	0.00056	0.000772	CcSEcCtD
Galantamine—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000558	0.000771	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000558	0.00077	CcSEcCtD
Galantamine—Paraesthesia—Risedronate—osteoporosis	0.000557	0.000768	CcSEcCtD
Galantamine—Discomfort—Zoledronate—osteoporosis	0.000555	0.000766	CcSEcCtD
Galantamine—Asthenia—Alendronate—osteoporosis	0.000554	0.000765	CcSEcCtD
Galantamine—Hypersensitivity—Ibandronate—osteoporosis	0.000554	0.000765	CcSEcCtD
Galantamine—Cough—Conjugated Estrogens—osteoporosis	0.000554	0.000765	CcSEcCtD
Galantamine—Hypotension—Pamidronate—osteoporosis	0.000551	0.00076	CcSEcCtD
Galantamine—Convulsion—Conjugated Estrogens—osteoporosis	0.00055	0.00076	CcSEcCtD
Galantamine—Dry mouth—Zoledronate—osteoporosis	0.000549	0.000758	CcSEcCtD
Galantamine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000549	0.000758	CcSEcCtD
Galantamine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000548	0.000757	CcSEcCtD
Galantamine—Dyspepsia—Risedronate—osteoporosis	0.000546	0.000753	CcSEcCtD
Galantamine—Eye disorder—Estradiol—osteoporosis	0.000546	0.000753	CcSEcCtD
Galantamine—Tinnitus—Estradiol—osteoporosis	0.000544	0.000752	CcSEcCtD
Galantamine—Constipation—Ethinyl Estradiol—osteoporosis	0.000544	0.000751	CcSEcCtD
Galantamine—Confusional state—Zoledronate—osteoporosis	0.000543	0.000749	CcSEcCtD
Galantamine—Hypersensitivity—Calcitriol—osteoporosis	0.000543	0.000749	CcSEcCtD
Galantamine—Flushing—Estradiol—osteoporosis	0.000542	0.000748	CcSEcCtD
Galantamine—Cardiac disorder—Estradiol—osteoporosis	0.000542	0.000748	CcSEcCtD
Galantamine—Chest pain—Conjugated Estrogens—osteoporosis	0.000541	0.000746	CcSEcCtD
Galantamine—Myalgia—Conjugated Estrogens—osteoporosis	0.000541	0.000746	CcSEcCtD
Galantamine—Arthralgia—Conjugated Estrogens—osteoporosis	0.000541	0.000746	CcSEcCtD
Galantamine—Asthenia—Ibandronate—osteoporosis	0.00054	0.000745	CcSEcCtD
Galantamine—Anxiety—Conjugated Estrogens—osteoporosis	0.000539	0.000744	CcSEcCtD
Galantamine—Nausea—Etidronic acid—osteoporosis	0.000539	0.000743	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000537	0.000741	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000537	0.000741	CcSEcCtD
Galantamine—Diarrhoea—Estropipate—osteoporosis	0.000537	0.000741	CcSEcCtD
Galantamine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000535	0.000739	CcSEcCtD
Galantamine—Fatigue—Risedronate—osteoporosis	0.000535	0.000738	CcSEcCtD
Galantamine—Insomnia—Pamidronate—osteoporosis	0.000533	0.000736	CcSEcCtD
Galantamine—Constipation—Risedronate—osteoporosis	0.00053	0.000732	CcSEcCtD
Galantamine—Angiopathy—Estradiol—osteoporosis	0.00053	0.000731	CcSEcCtD
Galantamine—Shock—Zoledronate—osteoporosis	0.00053	0.000731	CcSEcCtD
Galantamine—Paraesthesia—Pamidronate—osteoporosis	0.000529	0.00073	CcSEcCtD
Galantamine—Diarrhoea—Alendronate—osteoporosis	0.000529	0.00073	CcSEcCtD
Galantamine—Asthenia—Calcitriol—osteoporosis	0.000528	0.000729	CcSEcCtD
Galantamine—Nervous system disorder—Zoledronate—osteoporosis	0.000528	0.000729	CcSEcCtD
Galantamine—Immune system disorder—Estradiol—osteoporosis	0.000527	0.000728	CcSEcCtD
Galantamine—Thrombocytopenia—Zoledronate—osteoporosis	0.000527	0.000728	CcSEcCtD
Galantamine—Tachycardia—Zoledronate—osteoporosis	0.000525	0.000725	CcSEcCtD
Galantamine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000524	0.000723	CcSEcCtD
Galantamine—Somnolence—Pamidronate—osteoporosis	0.000524	0.000723	CcSEcCtD
Galantamine—Skin disorder—Zoledronate—osteoporosis	0.000523	0.000722	CcSEcCtD
Galantamine—Hyperhidrosis—Zoledronate—osteoporosis	0.00052	0.000718	CcSEcCtD
Galantamine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00052	0.000718	CcSEcCtD
Galantamine—Diarrhoea—Raloxifene—osteoporosis	0.00052	0.000718	CcSEcCtD
Galantamine—Dyspepsia—Pamidronate—osteoporosis	0.000519	0.000716	CcSEcCtD
Galantamine—Dizziness—Estropipate—osteoporosis	0.000519	0.000716	CcSEcCtD
Galantamine—Diarrhoea—Ibandronate—osteoporosis	0.000515	0.00071	CcSEcCtD
Galantamine—Anorexia—Zoledronate—osteoporosis	0.000513	0.000708	CcSEcCtD
Galantamine—Decreased appetite—Pamidronate—osteoporosis	0.000512	0.000707	CcSEcCtD
Galantamine—Mental disorder—Estradiol—osteoporosis	0.000512	0.000706	CcSEcCtD
Galantamine—Dizziness—Alendronate—osteoporosis	0.000511	0.000705	CcSEcCtD
Galantamine—Shock—Conjugated Estrogens—osteoporosis	0.00051	0.000704	CcSEcCtD
Galantamine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000509	0.000702	CcSEcCtD
Galantamine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000508	0.000702	CcSEcCtD
Galantamine—Malnutrition—Estradiol—osteoporosis	0.000508	0.000702	CcSEcCtD
Galantamine—Fatigue—Pamidronate—osteoporosis	0.000508	0.000701	CcSEcCtD
Galantamine—Gastrointestinal pain—Risedronate—osteoporosis	0.000507	0.0007	CcSEcCtD
Galantamine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000506	0.000698	CcSEcCtD
Galantamine—Constipation—Pamidronate—osteoporosis	0.000504	0.000696	CcSEcCtD
Galantamine—Diarrhoea—Calcitriol—osteoporosis	0.000504	0.000695	CcSEcCtD
Galantamine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000504	0.000695	CcSEcCtD
Galantamine—Hypotension—Zoledronate—osteoporosis	0.000503	0.000694	CcSEcCtD
Galantamine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000503	0.000694	CcSEcCtD
Galantamine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000503	0.000694	CcSEcCtD
Galantamine—Dizziness—Raloxifene—osteoporosis	0.000503	0.000694	CcSEcCtD
Galantamine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000501	0.000692	CcSEcCtD
Galantamine—Flatulence—Estradiol—osteoporosis	0.000501	0.000691	CcSEcCtD
Galantamine—Tension—Estradiol—osteoporosis	0.000499	0.000689	CcSEcCtD
Galantamine—Vomiting—Estropipate—osteoporosis	0.000499	0.000688	CcSEcCtD
Galantamine—Dysgeusia—Estradiol—osteoporosis	0.000498	0.000687	CcSEcCtD
Galantamine—Dizziness—Ibandronate—osteoporosis	0.000497	0.000687	CcSEcCtD
Galantamine—Rash—Estropipate—osteoporosis	0.000495	0.000683	CcSEcCtD
Galantamine—Dermatitis—Estropipate—osteoporosis	0.000494	0.000682	CcSEcCtD
Galantamine—Anorexia—Conjugated Estrogens—osteoporosis	0.000494	0.000682	CcSEcCtD
Galantamine—Nervousness—Estradiol—osteoporosis	0.000494	0.000681	CcSEcCtD
Galantamine—Back pain—Estradiol—osteoporosis	0.000492	0.000679	CcSEcCtD
Galantamine—Headache—Estropipate—osteoporosis	0.000491	0.000678	CcSEcCtD
Galantamine—Vomiting—Alendronate—osteoporosis	0.000491	0.000678	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00049	0.000677	CcSEcCtD
Galantamine—Body temperature increased—Risedronate—osteoporosis	0.00049	0.000676	CcSEcCtD
Galantamine—Abdominal pain—Risedronate—osteoporosis	0.00049	0.000676	CcSEcCtD
Galantamine—Muscle spasms—Estradiol—osteoporosis	0.000489	0.000675	CcSEcCtD
Galantamine—Rash—Alendronate—osteoporosis	0.000487	0.000672	CcSEcCtD
Galantamine—Insomnia—Zoledronate—osteoporosis	0.000487	0.000672	CcSEcCtD
Galantamine—Dermatitis—Alendronate—osteoporosis	0.000487	0.000672	CcSEcCtD
Galantamine—Feeling abnormal—Pamidronate—osteoporosis	0.000486	0.00067	CcSEcCtD
Galantamine—Hypotension—Conjugated Estrogens—osteoporosis	0.000484	0.000669	CcSEcCtD
Galantamine—Headache—Alendronate—osteoporosis	0.000484	0.000668	CcSEcCtD
Galantamine—Paraesthesia—Zoledronate—osteoporosis	0.000483	0.000667	CcSEcCtD
Galantamine—Vomiting—Raloxifene—osteoporosis	0.000483	0.000667	CcSEcCtD
Galantamine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000482	0.000665	CcSEcCtD
Galantamine—Rash—Raloxifene—osteoporosis	0.000479	0.000661	CcSEcCtD
Galantamine—Dermatitis—Raloxifene—osteoporosis	0.000479	0.000661	CcSEcCtD
Galantamine—Somnolence—Zoledronate—osteoporosis	0.000479	0.000661	CcSEcCtD
Galantamine—Vomiting—Ibandronate—osteoporosis	0.000478	0.00066	CcSEcCtD
Galantamine—Tremor—Estradiol—osteoporosis	0.000476	0.000657	CcSEcCtD
Galantamine—Headache—Raloxifene—osteoporosis	0.000476	0.000657	CcSEcCtD
Galantamine—Rash—Ibandronate—osteoporosis	0.000474	0.000655	CcSEcCtD
Galantamine—Dermatitis—Ibandronate—osteoporosis	0.000474	0.000654	CcSEcCtD
Galantamine—Dyspepsia—Zoledronate—osteoporosis	0.000474	0.000654	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000472	0.000652	CcSEcCtD
Galantamine—Ill-defined disorder—Estradiol—osteoporosis	0.000472	0.000651	CcSEcCtD
Galantamine—Headache—Ibandronate—osteoporosis	0.000471	0.000651	CcSEcCtD
Galantamine—Insomnia—Conjugated Estrogens—osteoporosis	0.000469	0.000647	CcSEcCtD
Galantamine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000469	0.000647	CcSEcCtD
Galantamine—Vomiting—Calcitriol—osteoporosis	0.000468	0.000646	CcSEcCtD
Galantamine—Decreased appetite—Zoledronate—osteoporosis	0.000468	0.000646	CcSEcCtD
Galantamine—Agitation—Estradiol—osteoporosis	0.000467	0.000645	CcSEcCtD
Galantamine—Nausea—Estropipate—osteoporosis	0.000466	0.000643	CcSEcCtD
Galantamine—Abdominal pain—Pamidronate—osteoporosis	0.000466	0.000643	CcSEcCtD
Galantamine—Body temperature increased—Pamidronate—osteoporosis	0.000466	0.000643	CcSEcCtD
Galantamine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000465	0.000642	CcSEcCtD
Galantamine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000465	0.000642	CcSEcCtD
Galantamine—Rash—Calcitriol—osteoporosis	0.000464	0.000641	CcSEcCtD
Galantamine—Fatigue—Zoledronate—osteoporosis	0.000464	0.000641	CcSEcCtD
Galantamine—Dermatitis—Calcitriol—osteoporosis	0.000464	0.00064	CcSEcCtD
Galantamine—Headache—Calcitriol—osteoporosis	0.000461	0.000637	CcSEcCtD
Galantamine—Somnolence—Conjugated Estrogens—osteoporosis	0.000461	0.000636	CcSEcCtD
Galantamine—Constipation—Zoledronate—osteoporosis	0.00046	0.000635	CcSEcCtD
Galantamine—Nausea—Alendronate—osteoporosis	0.000459	0.000634	CcSEcCtD
Galantamine—Malaise—Estradiol—osteoporosis	0.000458	0.000633	CcSEcCtD
Galantamine—Hypersensitivity—Risedronate—osteoporosis	0.000457	0.00063	CcSEcCtD
Galantamine—Vertigo—Estradiol—osteoporosis	0.000457	0.00063	CcSEcCtD
Galantamine—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000456	0.00063	CcSEcCtD
Galantamine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000456	0.00063	CcSEcCtD
Galantamine—Syncope—Estradiol—osteoporosis	0.000456	0.000629	CcSEcCtD
Galantamine—Nausea—Raloxifene—osteoporosis	0.000451	0.000623	CcSEcCtD
Galantamine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000451	0.000622	CcSEcCtD
Galantamine—Palpitations—Estradiol—osteoporosis	0.000449	0.00062	CcSEcCtD
Galantamine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000448	0.000618	CcSEcCtD
Galantamine—Fatigue—Conjugated Estrogens—osteoporosis	0.000447	0.000617	CcSEcCtD
Galantamine—Nausea—Ibandronate—osteoporosis	0.000447	0.000617	CcSEcCtD
Galantamine—Loss of consciousness—Estradiol—osteoporosis	0.000447	0.000617	CcSEcCtD
Galantamine—Asthenia—Risedronate—osteoporosis	0.000445	0.000614	CcSEcCtD
Galantamine—Feeling abnormal—Zoledronate—osteoporosis	0.000444	0.000612	CcSEcCtD
Galantamine—Cough—Estradiol—osteoporosis	0.000444	0.000612	CcSEcCtD
Galantamine—Constipation—Conjugated Estrogens—osteoporosis	0.000443	0.000612	CcSEcCtD
Galantamine—Gastrointestinal pain—Zoledronate—osteoporosis	0.00044	0.000608	CcSEcCtD
Galantamine—Hypertension—Estradiol—osteoporosis	0.000439	0.000606	CcSEcCtD
Galantamine—Nausea—Calcitriol—osteoporosis	0.000437	0.000604	CcSEcCtD
Galantamine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000435	0.000601	CcSEcCtD
Galantamine—Hypersensitivity—Pamidronate—osteoporosis	0.000434	0.000599	CcSEcCtD
Galantamine—Myalgia—Estradiol—osteoporosis	0.000433	0.000597	CcSEcCtD
Galantamine—Arthralgia—Estradiol—osteoporosis	0.000433	0.000597	CcSEcCtD
Galantamine—Chest pain—Estradiol—osteoporosis	0.000433	0.000597	CcSEcCtD
Galantamine—Anxiety—Estradiol—osteoporosis	0.000431	0.000595	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00043	0.000593	CcSEcCtD
Galantamine—Discomfort—Estradiol—osteoporosis	0.000428	0.00059	CcSEcCtD
Galantamine—Body temperature increased—Zoledronate—osteoporosis	0.000426	0.000587	CcSEcCtD
Galantamine—Abdominal pain—Zoledronate—osteoporosis	0.000426	0.000587	CcSEcCtD
Galantamine—Diarrhoea—Risedronate—osteoporosis	0.000424	0.000586	CcSEcCtD
Galantamine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000424	0.000585	CcSEcCtD
Galantamine—Dry mouth—Estradiol—osteoporosis	0.000423	0.000584	CcSEcCtD
Galantamine—Asthenia—Pamidronate—osteoporosis	0.000423	0.000584	CcSEcCtD
Galantamine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000421	0.00058	CcSEcCtD
Galantamine—Confusional state—Estradiol—osteoporosis	0.000418	0.000577	CcSEcCtD
Galantamine—Dizziness—Risedronate—osteoporosis	0.00041	0.000566	CcSEcCtD
Galantamine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00041	0.000566	CcSEcCtD
Galantamine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00041	0.000566	CcSEcCtD
Galantamine—Shock—Estradiol—osteoporosis	0.000408	0.000563	CcSEcCtD
Galantamine—Nervous system disorder—Estradiol—osteoporosis	0.000407	0.000562	CcSEcCtD
Galantamine—Tachycardia—Estradiol—osteoporosis	0.000405	0.000559	CcSEcCtD
Galantamine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000404	0.000558	CcSEcCtD
Galantamine—Diarrhoea—Pamidronate—osteoporosis	0.000403	0.000557	CcSEcCtD
Galantamine—Skin disorder—Estradiol—osteoporosis	0.000403	0.000556	CcSEcCtD
Galantamine—Hyperhidrosis—Estradiol—osteoporosis	0.000401	0.000554	CcSEcCtD
Galantamine—Rash—Ethinyl Estradiol—osteoporosis	0.000401	0.000553	CcSEcCtD
Galantamine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000401	0.000553	CcSEcCtD
Galantamine—Headache—Ethinyl Estradiol—osteoporosis	0.000398	0.00055	CcSEcCtD
Galantamine—Hypersensitivity—Zoledronate—osteoporosis	0.000397	0.000547	CcSEcCtD
Galantamine—Vomiting—Risedronate—osteoporosis	0.000394	0.000544	CcSEcCtD
Galantamine—Rash—Risedronate—osteoporosis	0.000391	0.00054	CcSEcCtD
Galantamine—Dermatitis—Risedronate—osteoporosis	0.000391	0.000539	CcSEcCtD
Galantamine—Dizziness—Pamidronate—osteoporosis	0.00039	0.000538	CcSEcCtD
Galantamine—Headache—Risedronate—osteoporosis	0.000388	0.000536	CcSEcCtD
Galantamine—Asthenia—Zoledronate—osteoporosis	0.000386	0.000533	CcSEcCtD
Galantamine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000382	0.000527	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000378	0.000522	CcSEcCtD
Galantamine—Nausea—Ethinyl Estradiol—osteoporosis	0.000378	0.000521	CcSEcCtD
Galantamine—Insomnia—Estradiol—osteoporosis	0.000375	0.000518	CcSEcCtD
Galantamine—Vomiting—Pamidronate—osteoporosis	0.000375	0.000517	CcSEcCtD
Galantamine—Paraesthesia—Estradiol—osteoporosis	0.000373	0.000514	CcSEcCtD
Galantamine—Asthenia—Conjugated Estrogens—osteoporosis	0.000372	0.000513	CcSEcCtD
Galantamine—Rash—Pamidronate—osteoporosis	0.000372	0.000513	CcSEcCtD
Galantamine—Dermatitis—Pamidronate—osteoporosis	0.000371	0.000512	CcSEcCtD
Galantamine—Headache—Pamidronate—osteoporosis	0.000369	0.00051	CcSEcCtD
Galantamine—Somnolence—Estradiol—osteoporosis	0.000369	0.000509	CcSEcCtD
Galantamine—Diarrhoea—Zoledronate—osteoporosis	0.000368	0.000508	CcSEcCtD
Galantamine—Nausea—Risedronate—osteoporosis	0.000368	0.000508	CcSEcCtD
Galantamine—Dyspepsia—Estradiol—osteoporosis	0.000365	0.000504	CcSEcCtD
Galantamine—Decreased appetite—Estradiol—osteoporosis	0.000361	0.000498	CcSEcCtD
Galantamine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000358	0.000494	CcSEcCtD
Galantamine—Fatigue—Estradiol—osteoporosis	0.000358	0.000494	CcSEcCtD
Galantamine—Dizziness—Zoledronate—osteoporosis	0.000356	0.000491	CcSEcCtD
Galantamine—Constipation—Estradiol—osteoporosis	0.000355	0.00049	CcSEcCtD
Galantamine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000355	0.00049	CcSEcCtD
Galantamine—Nausea—Pamidronate—osteoporosis	0.00035	0.000483	CcSEcCtD
Galantamine—Dizziness—Conjugated Estrogens—osteoporosis	0.000343	0.000473	CcSEcCtD
Galantamine—Vomiting—Zoledronate—osteoporosis	0.000342	0.000472	CcSEcCtD
Galantamine—Feeling abnormal—Estradiol—osteoporosis	0.000342	0.000472	CcSEcCtD
Galantamine—Rash—Zoledronate—osteoporosis	0.000339	0.000469	CcSEcCtD
Galantamine—Gastrointestinal pain—Estradiol—osteoporosis	0.000339	0.000468	CcSEcCtD
Galantamine—Dermatitis—Zoledronate—osteoporosis	0.000339	0.000468	CcSEcCtD
Galantamine—Headache—Zoledronate—osteoporosis	0.000337	0.000466	CcSEcCtD
Galantamine—Vomiting—Conjugated Estrogens—osteoporosis	0.00033	0.000455	CcSEcCtD
Galantamine—Body temperature increased—Estradiol—osteoporosis	0.000328	0.000453	CcSEcCtD
Galantamine—Abdominal pain—Estradiol—osteoporosis	0.000328	0.000453	CcSEcCtD
Galantamine—Rash—Conjugated Estrogens—osteoporosis	0.000327	0.000451	CcSEcCtD
Galantamine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000327	0.000451	CcSEcCtD
Galantamine—Headache—Conjugated Estrogens—osteoporosis	0.000325	0.000448	CcSEcCtD
Galantamine—Nausea—Zoledronate—osteoporosis	0.00032	0.000441	CcSEcCtD
Galantamine—Nausea—Conjugated Estrogens—osteoporosis	0.000308	0.000425	CcSEcCtD
Galantamine—Hypersensitivity—Estradiol—osteoporosis	0.000306	0.000422	CcSEcCtD
Galantamine—Asthenia—Estradiol—osteoporosis	0.000298	0.000411	CcSEcCtD
Galantamine—Diarrhoea—Estradiol—osteoporosis	0.000284	0.000392	CcSEcCtD
Galantamine—Dizziness—Estradiol—osteoporosis	0.000274	0.000379	CcSEcCtD
Galantamine—Vomiting—Estradiol—osteoporosis	0.000264	0.000364	CcSEcCtD
Galantamine—Rash—Estradiol—osteoporosis	0.000262	0.000361	CcSEcCtD
Galantamine—Dermatitis—Estradiol—osteoporosis	0.000261	0.000361	CcSEcCtD
Galantamine—Headache—Estradiol—osteoporosis	0.00026	0.000359	CcSEcCtD
Galantamine—Nausea—Estradiol—osteoporosis	0.000246	0.00034	CcSEcCtD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.00018	0.0121	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—REN—osteoporosis	0.000175	0.0118	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000166	0.0111	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.000163	0.011	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000159	0.0107	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—MGLL—osteoporosis	0.000157	0.0105	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—REN—osteoporosis	0.000156	0.0105	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000152	0.0102	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000151	0.0101	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000144	0.00968	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—MGLL—osteoporosis	0.00014	0.00941	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—ADCY5—osteoporosis	0.00014	0.00938	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000135	0.0091	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000134	0.009	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.000133	0.00894	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.00013	0.00876	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—ADCY5—osteoporosis	0.000122	0.0082	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—ADCY5—osteoporosis	0.000116	0.00777	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000114	0.00769	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000113	0.00761	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—ADCY5—osteoporosis	0.00011	0.00742	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—ACE—osteoporosis	0.000109	0.00735	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000107	0.00716	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	0.000105	0.00709	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—ADCY5—osteoporosis	0.000104	0.00697	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000101	0.00677	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.0001	0.00674	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	9.89e-05	0.00665	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—ACE—osteoporosis	9.76e-05	0.00656	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	9.65e-05	0.00648	CbGpPWpGaD
Galantamine—ACHE—Monoamine Transport—IL1B—osteoporosis	9.46e-05	0.00636	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—ESR2—osteoporosis	9.23e-05	0.0062	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	9.16e-05	0.00615	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	9.06e-05	0.00609	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL6R—osteoporosis	8.82e-05	0.00593	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—ADCY5—osteoporosis	8.77e-05	0.00589	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—ESR1—osteoporosis	8.69e-05	0.00584	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	8.61e-05	0.00579	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—LEP—osteoporosis	8.59e-05	0.00577	CbGpPWpGaD
Galantamine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	8.25e-05	0.00555	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	8.12e-05	0.00546	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—ADCY5—osteoporosis	8.01e-05	0.00538	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—ADCY5—osteoporosis	7.93e-05	0.00533	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	7.87e-05	0.00529	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—ADCY5—osteoporosis	7.72e-05	0.00519	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY5—osteoporosis	7.46e-05	0.00502	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—ADCY5—osteoporosis	7.25e-05	0.00487	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	7.03e-05	0.00473	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL6R—osteoporosis	6.94e-05	0.00466	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—ADCY5—osteoporosis	6.88e-05	0.00463	CbGpPWpGaD
Galantamine—ACHE—Monoamine Transport—TNF—osteoporosis	6.87e-05	0.00462	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—ADCY5—osteoporosis	6.81e-05	0.00458	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—LEP—osteoporosis	6.8e-05	0.00457	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL1B—osteoporosis	6.71e-05	0.00451	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	6.67e-05	0.00448	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	6.55e-05	0.0044	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—ADCY5—osteoporosis	6.47e-05	0.00435	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	6.47e-05	0.00435	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	6.28e-05	0.00422	CbGpPWpGaD
Galantamine—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	6.17e-05	0.00415	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—ADCY5—osteoporosis	6.14e-05	0.00413	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—ADCY5—osteoporosis	6.08e-05	0.00408	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—LEP—osteoporosis	6.06e-05	0.00407	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL6R—osteoporosis	6.02e-05	0.00405	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	5.95e-05	0.004	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—POMC—osteoporosis	5.84e-05	0.00392	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CCT2—osteoporosis	5.76e-05	0.00387	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—IGF1—osteoporosis	5.62e-05	0.00377	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—ADCY5—osteoporosis	5.61e-05	0.00377	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	5.6e-05	0.00376	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—ADCY5—osteoporosis	5.56e-05	0.00373	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	5.31e-05	0.00357	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL1B—osteoporosis	5.28e-05	0.00355	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—ADCY5—osteoporosis	5.27e-05	0.00354	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	5.26e-05	0.00354	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—ADCY5—osteoporosis	5.22e-05	0.00351	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—POMC—osteoporosis	5.21e-05	0.0035	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	5.2e-05	0.00349	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	5.19e-05	0.00349	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CCT2—osteoporosis	5.14e-05	0.00345	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	5.05e-05	0.0034	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—IGF1—osteoporosis	5.01e-05	0.00337	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—ADCY5—osteoporosis	4.96e-05	0.00333	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL6R—osteoporosis	4.91e-05	0.0033	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—TUBA1B—osteoporosis	4.9e-05	0.00329	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—TNF—osteoporosis	4.87e-05	0.00327	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	4.74e-05	0.00319	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	4.63e-05	0.00311	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL1B—osteoporosis	4.58e-05	0.00308	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	4.51e-05	0.00303	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—TUBA1B—osteoporosis	4.37e-05	0.00294	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP27A1—osteoporosis	4.32e-05	0.0029	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—ADCY5—osteoporosis	4.3e-05	0.00289	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	4.27e-05	0.00287	CbGpPWpGaD
Galantamine—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	4.26e-05	0.00286	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP27A1—osteoporosis	4.26e-05	0.00286	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.04e-05	0.00272	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—ADCY5—osteoporosis	4e-05	0.00269	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL6—osteoporosis	3.93e-05	0.00264	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—RPL24—osteoporosis	3.92e-05	0.00263	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—TNF—osteoporosis	3.83e-05	0.00258	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL1B—osteoporosis	3.74e-05	0.00251	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	3.6e-05	0.00242	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—ADCY5—osteoporosis	3.57e-05	0.0024	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—RPL24—osteoporosis	3.49e-05	0.00235	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—TLN1—osteoporosis	3.44e-05	0.00231	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	3.44e-05	0.00231	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.44e-05	0.00231	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—IL6—osteoporosis	3.4e-05	0.00228	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	3.4e-05	0.00228	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	3.39e-05	0.00228	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—TNF—osteoporosis	3.33e-05	0.00223	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—REN—osteoporosis	3.31e-05	0.00222	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—IL6—osteoporosis	3.21e-05	0.00216	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	3.16e-05	0.00213	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PKM—osteoporosis	3.13e-05	0.00211	CbGpPWpGaD
Galantamine—ACHE—Metabolism—FDPS—osteoporosis	3.13e-05	0.00211	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL6—osteoporosis	3.09e-05	0.00208	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—TLN1—osteoporosis	3.07e-05	0.00206	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—ADCY5—osteoporosis	3.07e-05	0.00206	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.06e-05	0.00206	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GPD2—osteoporosis	2.97e-05	0.002	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PGLS—osteoporosis	2.97e-05	0.002	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—REN—osteoporosis	2.95e-05	0.00198	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.94e-05	0.00197	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	2.82e-05	0.0019	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PKM—osteoporosis	2.79e-05	0.00188	CbGpPWpGaD
Galantamine—BCHE—Metabolism—FDPS—osteoporosis	2.79e-05	0.00188	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	2.79e-05	0.00188	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	2.78e-05	0.00187	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—ADCY5—osteoporosis	2.74e-05	0.00184	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PNP—osteoporosis	2.72e-05	0.00183	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ATIC—osteoporosis	2.72e-05	0.00183	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—TNF—osteoporosis	2.71e-05	0.00182	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL6—osteoporosis	2.68e-05	0.0018	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PGLS—osteoporosis	2.65e-05	0.00178	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GPD2—osteoporosis	2.65e-05	0.00178	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—osteoporosis	2.56e-05	0.00172	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ATIC—osteoporosis	2.42e-05	0.00163	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PNP—osteoporosis	2.42e-05	0.00163	CbGpPWpGaD
Galantamine—ACHE—Metabolism—OXCT1—osteoporosis	2.31e-05	0.00155	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CA2—osteoporosis	2.31e-05	0.00155	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	2.27e-05	0.00152	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MGLL—osteoporosis	2.25e-05	0.00151	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	2.24e-05	0.0015	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL6—osteoporosis	2.19e-05	0.00147	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.12e-05	0.00143	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	2.07e-05	0.00139	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—ACE—osteoporosis	2.07e-05	0.00139	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CA2—osteoporosis	2.06e-05	0.00138	CbGpPWpGaD
Galantamine—BCHE—Metabolism—OXCT1—osteoporosis	2.06e-05	0.00138	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MGLL—osteoporosis	2.01e-05	0.00135	CbGpPWpGaD
Galantamine—ACHE—Metabolism—IDH2—osteoporosis	1.91e-05	0.00129	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.89e-05	0.00127	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—ACE—osteoporosis	1.84e-05	0.00124	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP27A1—osteoporosis	1.8e-05	0.00121	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.77e-05	0.00119	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.76e-05	0.00118	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ACP5—osteoporosis	1.75e-05	0.00118	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.73e-05	0.00116	CbGpPWpGaD
Galantamine—BCHE—Metabolism—IDH2—osteoporosis	1.71e-05	0.00115	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	1.68e-05	0.00113	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.64e-05	0.00111	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TPI1—osteoporosis	1.63e-05	0.00109	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP27A1—osteoporosis	1.61e-05	0.00108	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ACP5—osteoporosis	1.56e-05	0.00105	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.54e-05	0.00104	CbGpPWpGaD
Galantamine—ACHE—Metabolism—P4HB—osteoporosis	1.53e-05	0.00103	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GAPDH—osteoporosis	1.5e-05	0.00101	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	1.48e-05	0.000996	CbGpPWpGaD
Galantamine—ACHE—Metabolism—RAP1A—osteoporosis	1.46e-05	0.000983	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	1.46e-05	0.000982	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TPI1—osteoporosis	1.45e-05	0.000976	CbGpPWpGaD
Galantamine—BCHE—Metabolism—P4HB—osteoporosis	1.36e-05	0.000917	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—POMC—osteoporosis	1.36e-05	0.000916	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GAPDH—osteoporosis	1.34e-05	0.0009	CbGpPWpGaD
Galantamine—BCHE—Metabolism—RAP1A—osteoporosis	1.3e-05	0.000877	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—FDPS—osteoporosis	1.29e-05	0.000864	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PKM—osteoporosis	1.29e-05	0.000864	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—LEP—osteoporosis	1.28e-05	0.000862	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.28e-05	0.000857	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PGLS—osteoporosis	1.22e-05	0.000819	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GPD2—osteoporosis	1.22e-05	0.000819	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ENO1—osteoporosis	1.18e-05	0.000795	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PSMA2—osteoporosis	1.17e-05	0.000783	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PSMA5—osteoporosis	1.17e-05	0.000783	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—LEP—osteoporosis	1.14e-05	0.000769	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.14e-05	0.000765	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ATIC—osteoporosis	1.11e-05	0.000749	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PNP—osteoporosis	1.11e-05	0.000749	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—POMC—osteoporosis	1.1e-05	0.000741	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—IGF1—osteoporosis	1.06e-05	0.000712	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ENO1—osteoporosis	1.05e-05	0.000709	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PSMA2—osteoporosis	1.04e-05	0.000699	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PSMA5—osteoporosis	1.04e-05	0.000699	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—POMC—osteoporosis	9.83e-06	0.000661	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—OXCT1—osteoporosis	9.47e-06	0.000637	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CA2—osteoporosis	9.47e-06	0.000637	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—IGF1—osteoporosis	9.46e-06	0.000636	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP19A1—osteoporosis	9.45e-06	0.000635	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MGLL—osteoporosis	9.23e-06	0.00062	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—POMC—osteoporosis	8.91e-06	0.000599	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP19A1—osteoporosis	8.43e-06	0.000567	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PKM—osteoporosis	8.4e-06	0.000565	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—FDPS—osteoporosis	8.4e-06	0.000565	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GPD2—osteoporosis	7.96e-06	0.000535	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PGLS—osteoporosis	7.96e-06	0.000535	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—IDH2—osteoporosis	7.85e-06	0.000528	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ADCY5—osteoporosis	7.72e-06	0.000519	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GPX1—osteoporosis	7.7e-06	0.000517	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP27A1—osteoporosis	7.38e-06	0.000496	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PNP—osteoporosis	7.28e-06	0.00049	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ATIC—osteoporosis	7.28e-06	0.00049	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ACP5—osteoporosis	7.18e-06	0.000483	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MTHFR—osteoporosis	7.1e-06	0.000477	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ADCY5—osteoporosis	6.89e-06	0.000463	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GPX1—osteoporosis	6.87e-06	0.000461	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TPI1—osteoporosis	6.67e-06	0.000449	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MTHFR—osteoporosis	6.34e-06	0.000426	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—P4HB—osteoporosis	6.28e-06	0.000422	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CA2—osteoporosis	6.19e-06	0.000416	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—OXCT1—osteoporosis	6.19e-06	0.000416	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GAPDH—osteoporosis	6.16e-06	0.000414	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MGLL—osteoporosis	6.04e-06	0.000406	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—RAP1A—osteoporosis	6e-06	0.000403	CbGpPWpGaD
Galantamine—ACHE—Metabolism—POMC—osteoporosis	5.68e-06	0.000382	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—IDH2—osteoporosis	5.13e-06	0.000345	CbGpPWpGaD
Galantamine—BCHE—Metabolism—POMC—osteoporosis	5.07e-06	0.000341	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ENO1—osteoporosis	4.85e-06	0.000326	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP27A1—osteoporosis	4.83e-06	0.000324	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PSMA2—osteoporosis	4.78e-06	0.000321	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PSMA5—osteoporosis	4.78e-06	0.000321	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ACP5—osteoporosis	4.69e-06	0.000315	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TPI1—osteoporosis	4.36e-06	0.000293	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—P4HB—osteoporosis	4.1e-06	0.000276	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GAPDH—osteoporosis	4.03e-06	0.000271	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—RAP1A—osteoporosis	3.92e-06	0.000264	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP19A1—osteoporosis	3.88e-06	0.000261	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ENO1—osteoporosis	3.17e-06	0.000213	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ADCY5—osteoporosis	3.17e-06	0.000213	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GPX1—osteoporosis	3.16e-06	0.000212	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PSMA2—osteoporosis	3.12e-06	0.00021	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PSMA5—osteoporosis	3.12e-06	0.00021	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MTHFR—osteoporosis	2.91e-06	0.000196	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.53e-06	0.00017	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—POMC—osteoporosis	2.33e-06	0.000157	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ADCY5—osteoporosis	2.07e-06	0.000139	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GPX1—osteoporosis	2.06e-06	0.000139	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MTHFR—osteoporosis	1.9e-06	0.000128	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—POMC—osteoporosis	1.52e-06	0.000102	CbGpPWpGaD
